SYnAbs’ mission is to generate innovative monoclonal antibodies against poor immunogenic compounds and complex antigens. Either as a custom service, or as a catalog product, IVD and Biotech players benefit from SYnAbs technologies to get access to singular binder (small molecules) and effector antibodies (transmembrane protein, GPCR, ion channels…)

SYnAbs is a CRO providing one-stop-shop solution with dedicated experienced project managers: from animal housing, immunization, antigen design and production, custom manufacturing up to several grams of purified antibodies, development of custom immunoassays, humanization for therapeutic purposes, antibody engineering…

Website

https://www.synabs.be/

LinkedIn

Contact

Julien Isoard, CEO

[email protected] – +32 483 743 904